摘要
目的探讨天津地区慢性乙型肝炎病毒(HBV)感染者的血清标志物模式及其特征。方法采用电化学免疫发光分析法对天津地区8 577例慢性HBV感染者的血清标志物进行定量检测,分析其模式组合方式,并按照年龄、性别进行分层研究。结果血清标志物共有18种不同组合模式,其中模式1(HBsAg+、HBeAb+、HBcAb+)占比例最高,为40.00%;其次为模式2(HBsAg+、HBeAg+、HBcAb+),所占比例为27.14%;特殊血清学模式(HBsAg+、HBsAb+)所占比例为5.50%。男性HBV感染者血清标志物模式1、2所占比例均高于女性(P<0.05或<0.01)。20~40<岁年龄组血清标志物模式1、2所占比例分别为49.58%和62.16%,均高于其他年龄组(P<0.05或<0.01)。结论天津地区慢性HBV感染者以HBsAg+、HBeAb+、HBcAb+和HBsAg+、HBeAg+、HBcAb+为主要血清标志物模式;上述两种血清标志物模式在20~<40岁年龄组所占比例最高,在男性感染者中所占比例均高于女性。
Objective To analyze the models and characteristics of hepatitis B virus (HBV) serum markers in pa- tients with chronic hepatitis B from Tianjin area. Methods HBV serum markers of 8 577 patients with chronic hepatitis B from Tianjin area were detected by the electrochemical luminescence immunoassay (ECLIA). The different models of HBV serum markers were analyzed and stratified by age and gender. Results There were 18 models of HBV serum markers in this study. Model 1 (HBsAg +, anti-HBe +, anti-HBc + ) (40%) and model 2 (HBsAg +, HBeAg +, anti-HBc + ) (27.14%) were predominant. When stratified with age and gender, we found that the proportion was higher in 20 to 39- year-old patients of these two models (49.58%, 62.16%, respectively) and there were more males than females (P 〈 0. 05 or P 〈 0.01 ). The models with both positive HBsAg and anti-HBs accounted for 5.5%. The proportion was lower in patients less than 20 years old in model 1 and model 2 (0.61%, 2.58%, respectively). Conclusions The models of HBsAg +, HBeAg +, HBcAb + and the model of HBsAg + , HBeAb +, HBcAb + were the main patterns of chronic hepatitis B patients in Tianjin area. The proportion was higher in 20 to 39-year-old patients of these two models and there were more males than females.
作者
霍志晓
张世田
乔坤艳
代庆海
陆伟
侯伟
HUO Zhixiao ZHANG Shitian QIAO Kunyan DAI Qinghai LU Wei HOU Wei(Tianjin Second People's Hospital, Tianfin Institute of Hepatology, Tianjin 300192, China)
出处
《山东医药》
CAS
北大核心
2017年第12期5-7,共3页
Shandong Medical Journal
基金
国家自然科学基金资助项目(30800974/81271845)
天津市卫生局科技基金重点项目(2012KR02)
天津市卫生局科技基金攻关项目(12KG118)